Research in Cairo Cure | Cairo Cure Oncology Center

Published prospective
clinical trials

Research in Cairo Cure

Journal: The Breast

Year: 2022

Brief Description: This is an international trial involving thousands of women that evaluated novel formulation of the targeted treatment trastuzumab in managing breast cancer. This study led to the FDA approval of the subcutaneous form of trastuzumab which is now being used in clinical practice.

Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study.

Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.

Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.

OSSMAR: An Observational Study to Describe the Use of Sunitinib in Real-Life Practice for the Treatment of Metastatic Renal Cell Carcinoma.

Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study).

Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study.

A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma.

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.

A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer.

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.

Adjuvant trastuzumab in HER2-positive breast cancer.

Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study

Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: results of KINDLE-Egypt cohort

The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer

Clinicopathologic Features of Breast Cancer in Egypt-Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis.

Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.

Pathological features and prognosis of lobular carcinoma in Egyptian breast cancer patients.

One for the road! A study to assess the efficacy of single low-dose regimen of rasburicase in controlling hyperuricaemia in patients with tumour lysis syndrome due to haematological malignancies

Survey of utilization of multidisciplinary management tumor boards in Arab countries.

Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.

Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis

Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies

Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: a systematic overview

Safety of topical estrogen therapy during adjuvant endocrine treatment among patients with breast cancer: A meta-analysis based expert panel discussion

ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC).

Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer.

ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4).

Cancer and fertility preservation: international recommendations from an expert meeting.

Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup

First international consensus guidelines for breast cancer in young women (BCY1)

Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.

Modification and implementation of NCCN guidelines on lymphomas in the Middle East and North Africa region